Last edition
News about "Aptar Pharma"
Aptar Wins CE Mark for LuerVax Vaccine Delivery System
Aptar Pharma has secured CE marking for LuerVax and its spray divider, supporting intranasal vaccine development from clinical studies through commercialisation.
Aptar Pharma | 15/10/2026 | By News Bureau
Aptar and Aceso Therapeutics Partner on Inhaled Antisense Therapy for Cystic Fibrosis
Aptar and Aceso Therapeutics collaborate to advance inhaled antisense therapy ACT-101 for cystic fibrosis through formulation development and device assessment.
Aptar Pharma | 08/09/2026 | By News Bureau
Aptar Pharma Files Patents, Reports Positive Preclinical Data for GLP-1 Nasal and Pulmonary Delivery
Aptar Pharma announced new patent applications and positive preclinical data supporting intranasal and pulmonary GLP-1 delivery, expanding its capabilities in inhaled and intranasal biologic drug delivery.
Aptar Pharma | 29/05/2026 | By News Bureau | 203
Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
The collaboration between Aptar Pharma and COVIRIX Medical Partner will focus on a feasibility study to adapt Aptar Pharma’s proprietary Dry Powder Inhalation (DPI) platform for the delivery of COVIRIX Medical’s anti-viral compound.
Aptar Pharma | 16/03/2026 | By News Bureau | 118
Aptar Pharma and COVIRIX Medical Partner to Develop Inhalable Antiviral Treatments
The collaboration between Aptar Pharma and COVIRIX Medical Partner will focus on a feasibility study to adapt Aptar Pharma’s proprietary Dry Powder Inhalation (DPI) platform for the delivery of COVIRIX Medical’s anti-viral compound.
Aptar Pharma | 16/03/2026 | By News Bureau | 118
Aptar Acquires Sommaplast, Provider of Oral Dosing Pharma Packaging Solutions
The acquisition of Sommaplast strengthens Aptar’s pharmaceutical portfolio and expands its footprint in Latin America, giving the company access to Sommaplast’s established expertise in oral dosing components and its growing customer base across Brazil’s healthcare market.
Aptar Pharma | 04/12/2025 | By Dineshwori | 229
This acquisition builds on a successful partnership between the two companies, helping meet a critical market gap in early-phase clinical trial supply. The facility in Boonton, New Jersey—now part of Aptar’s operations—is FDA-inspected and houses cGMP cleanrooms, suites for high-potency APIs and biologics, and advanced fill-finish technologies.
Aptar Pharma | 16/07/2025 | By Darshana | 644
Aptar Pharma Acquires Device Technology Assets of SipNose
SipNose offers a variety of devices that are designed and adapted to fit a wide range of therapies and offer the opportunity to precisely target areas of the nasal cavity to enable enhanced systemic, local or even direct-to-brain delivery.
Aptar Pharma | 10/10/2024 | By Aishwarya | 573
Aptar Pharma Partners with Pulmotree to Develop Kolibri NPLI Platform
As part of the agreement, Aptar Pharma will provide PULMOTREE with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri NPLI Platform Technology with Aptar’s suite of comprehensive services.
Aptar Pharma | 10/09/2024 | By Aishwarya | 540
Aptar Pharma Gets NMPA Nod for Airless Drug Delivery System
Aptar Pharma has received approval by the National Medical Products Administration (NMPA) in China of Sinomune Pharmaceutical’s Li Fu metronidazole gel.
Aptar Pharma | 11/04/2024 | By Aishwarya | 1018
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy